Using PET/CT imaging to assess kidney inflammation and fibrosis
Clinical Study of Fibroblast Activating Protein Inhibitor (FAPI) -Mediated 18F Targeted to Evaluate Inflammation and Fibrosis in Renal Diseases
This study is testing a new imaging method using a special probe to see if it can help doctors better understand kidney inflammation and scarring in people with kidney diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 10 Years to 80 Years |
| Sex | All |
| Sponsor | Sichuan Provincial People's Hospital Academic / other |
| Locations | 1 site (Chengdu, Sichuan) |
| Trial ID | NCT05752097 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the feasibility of using a specific molecular probe, 18F-labeled FAP, for PET/CT imaging to assess inflammation and fibrosis in patients with renal diseases. Participants will undergo 18F-FAPI PET/CT imaging alongside renal aspiration biopsy to determine the accuracy and value of this non-invasive imaging technique. The study seeks to answer critical questions regarding the effectiveness of 18F-FAPI PET/CT in evaluating kidney conditions.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with nephritis or fibrosis-related kidney diseases.
Not a fit: Patients with severe uncontrolled hypertension, significant comorbidities, or those unable to undergo renal biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for accurately diagnosing and monitoring kidney inflammation and fibrosis.
How similar studies have performed: While the use of PET/CT imaging in renal diseases is an emerging field, similar studies have shown promising results in other areas of imaging and diagnostics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The pitients of nephritis or fibrosis disease Exclusion Criteria: * Hypertension that is difficult to control with medication, and systolic blood pressure exceeding 160mmHg * Renal biopsy cannot be performed for severe exclotting disease * Complicated with chronic liver disease, myocardial infarction, stroke, and malignant tumor * Unable to cooperate with renal puncture biopsy due to language communication or other problems * Female patients who are pregnant (or attempting to become pregnant within six months), breastfeeding, or unwilling to use contraception * Abnormal cardiopulmonary function or mental state, unable to tolerate prone lying for 20 minutes * Alcohol allergy * Patients with significant decrease in urine volume due to disease * Refusal to sign an informed consent form or inability or unwillingness to comply with the investigator-approved protocol * Other circumstances deemed inappropriate by the investigator for participation in the study.
Where this trial is running
Chengdu, Sichuan
- Sichuan Provincial People's Hospital — Chengdu, Sichuan, China (Recruiting)
Study contacts
- Study coordinator: Hao Wang, Principal Investigator
- Email: 18810566155@163.com
- Phone: +8618313820216
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.